Division of Genetic Medicine and Clinical Pharmacology

Melinda Aldrich, PhD, MPH

Melinda Aldrich elected to genetics society board of directors

Aldrich uses population-based cohorts and biobanks to investigate lung cancer; her research informed guidelines for lung cancer screening.

Peptide discovery could advance treatment of high blood pressure

VUMC researchers found that peptides modified by highly reactive compounds called isolevuglandins activated T cells and promoted hypertension in mice. Their first-ever isolation of such peptides is a step toward potentially intervening in this pathologic process.

$3.4 million research grant targets risk of heart attack, stroke

Making innovative use of observational data, researchers hope to gain new understanding of patient risk and identify existing drugs to lower risk.

GeneMAP discovery platform will help define functions for ‘orphan’ metabolic proteins 

The combination of genomics and metabolism identified a long-sought mitochondrial choline transporter.

Graduate student Taralynn Mack, left, pipettes a sample while Alexander Bick, MD, graduate student Hannah Poisner, and Celestine Wanjalla, MD, PhD, look on.

Research raises hope for treating potentially lethal blood condition

Roughly 1 in 10 people over age 70 will develop CHIP, an explosive, clonal growth of abnormal blood cells that increases risk of blood cancers and death from cardiovascular, lung and liver disease.

Photo caption: Jonathan Mosley, MD, PhD, left, Scott Borinstein, MD, PhD, John Shelley, and Vivian Kawai, MD, MPH, are studying how genetic variation not related to disease affects clinical decisions. (photo by Susan Urmy)

Genetic variation associated with low white blood cell count impacts clinical decisions

People whose white blood cell levels are near the edge of the “healthy” reference range will hit a clinical decision point that has consequences such as diagnostic procedures and altered treatments.

1 2 3 4 5 12